[go: up one dir, main page]

BR9912980A - Composição farmacêutica administrável oralmente, utilização de compostos, tablete de mascar e processos para evitar a sìndrome de vazamento anal de óleo - Google Patents

Composição farmacêutica administrável oralmente, utilização de compostos, tablete de mascar e processos para evitar a sìndrome de vazamento anal de óleo

Info

Publication number
BR9912980A
BR9912980A BR9912980-9A BR9912980A BR9912980A BR 9912980 A BR9912980 A BR 9912980A BR 9912980 A BR9912980 A BR 9912980A BR 9912980 A BR9912980 A BR 9912980A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compounds
processes
orally administrable
oil leakage
Prior art date
Application number
BR9912980-9A
Other languages
English (en)
Other versions
BR9912980B1 (pt
Inventor
Manuela Hug
Hans-Peter Maerki
Marcel Meier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9912980A publication Critical patent/BR9912980A/pt
Publication of BR9912980B1 publication Critical patent/BR9912980B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

<B><MU>COMPOSIçãO FARMACêUTICA ADMINISTRáVEL ORALMENTE, UTILIZAçãO DE COMPOSTOS, TABLETE DE MASCAR E PROCESSOS PARA EVITAR A SìNDROME DE VAZAMENTO ANAL DE óLEO<MV><D> Expõe-se uma composição farmacêutica administrável oralmente que contém um inibidor de lípase gastrintestinal, um (ou mais) aditivo(s) do grupo que consiste de espessadores e emulsionadores fracamente digeríveis, fracamente fermentáveis, hidrófilos e/ou hidrocolóides, e excipientes auxiliares.
BRPI9912980-9B1A 1998-08-14 1999-08-02 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma BR9912980B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98115311 1998-08-14
EP99109516 1999-05-12
PCT/EP1999/005607 WO2000009122A1 (en) 1998-08-14 1999-08-02 Pharmaceutical compositions containing lipase inhibitors

Publications (2)

Publication Number Publication Date
BR9912980A true BR9912980A (pt) 2001-05-08
BR9912980B1 BR9912980B1 (pt) 2013-10-22

Family

ID=26149537

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912980-9B1A BR9912980B1 (pt) 1998-08-14 1999-08-02 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma

Country Status (19)

Country Link
US (1) US6358522B1 (pt)
EP (1) EP1105122B1 (pt)
JP (1) JP3774118B2 (pt)
KR (1) KR20010079635A (pt)
CN (1) CN1170534C (pt)
AR (1) AR035001A1 (pt)
AT (1) ATE293970T1 (pt)
AU (1) AU761351B2 (pt)
BR (1) BR9912980B1 (pt)
CA (1) CA2340056C (pt)
CO (1) CO5130009A1 (pt)
DE (1) DE69924999T2 (pt)
DK (1) DK1105122T3 (pt)
ES (1) ES2242413T3 (pt)
MA (1) MA26671A1 (pt)
PE (1) PE20000953A1 (pt)
PT (1) PT1105122E (pt)
TR (1) TR200100471T2 (pt)
WO (1) WO2000009122A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
CA2342625A1 (en) 1998-09-08 2000-03-16 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
MXPA02012583A (es) * 2000-06-27 2003-04-10 Hoffmann La Roche Metodo para preparacion de una composicion.
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
JP4265911B2 (ja) * 2000-07-28 2009-05-20 エフ．ホフマン−ラ ロシュ アーゲー 新規医薬組成物
DE60133470T2 (de) 2000-08-09 2009-05-07 F. Hoffmann-La Roche Ag Lipase inhibitoren zur behandlung von dyspepsia
JP4047723B2 (ja) 2000-10-16 2008-02-13 エフ．ホフマン−ラ ロシュ アーゲー インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
US6610685B2 (en) 2000-12-27 2003-08-26 Hoffmann-La Roche Inc. Fused indole derivatives
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002338896B2 (en) 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
CN100383124C (zh) 2002-02-04 2008-04-23 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的喹啉衍生物
PL372463A1 (en) 2002-02-28 2005-07-25 F.Hoffmann-La Roche Ag Thiazole derivatives as npy receptor antagonists
CN1325050C (zh) 2002-04-26 2007-07-11 霍夫曼-拉罗奇有限公司 包含脂肪酶抑制剂和葡甘露聚糖的药物组合物
CN1665791A (zh) 2002-07-05 2005-09-07 霍夫曼-拉罗奇有限公司 喹唑啉衍生物
RU2324685C2 (ru) 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
PL375878A1 (en) 2002-09-12 2005-12-12 F.Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
BR0316556A (pt) 2002-11-25 2005-10-04 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende esse composto, sua utilização e método para o tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas ppar(alfa) e/ou ppary
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
KR20060037435A (ko) 2003-08-12 2006-05-03 에프. 호프만-라 로슈 아게 2-아미노-5-벤조일싸이아졸 ｎｐｙ 길항물질
DE602004019939D1 (de) 2003-08-12 2009-04-23 Hoffmann La Roche Thiazolderivate als npy-antagonisten
CA2609634C (en) 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
US20090208584A1 (en) 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
EP1945635B1 (en) 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
BRPI0619268A2 (pt) 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
RU2412182C2 (ru) 2005-11-30 2011-02-20 Ф.Хоффманн-Ля Рош Аг Производные 1,1-диоксотиоморфолинилиндолилметанона для применения в качестве модуляторов гистамина 3 (н3)
CA2630270A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
CA2631128A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
DE602006010738D1 (de) 2005-12-15 2010-01-07 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
WO2007068641A1 (en) 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo [2 , 3-b] pyridine derivatives as h3 receptor modulators
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2008014532A (es) 2006-05-30 2008-11-27 Hoffmann La Roche Derivados de piperidinil pirimidinas.
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US7862688B2 (en) * 2007-05-16 2011-01-04 Buckman Laboratories International, Inc. Methods to control organic contaminants in fibers
WO2009013195A1 (en) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
BR112018075415A2 (pt) * 2016-06-17 2019-03-12 The Procter & Gamble Company composição mastigável macia compreendendo plantago
CN112220831A (zh) * 2020-08-07 2021-01-15 天津盛实百草中药科技有限公司 圆苞车前子壳粉在缓解奥利司他副作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JPH09252746A (ja) * 1996-03-22 1997-09-30 Nippon Kankyo Yakuhin Kk 栄養補助食品
JP4202439B2 (ja) * 1996-10-01 2008-12-24 江崎グリコ株式会社 フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
CO5130009A1 (es) 2002-02-27
US6358522B1 (en) 2002-03-19
MA26671A1 (fr) 2004-12-20
DE69924999D1 (de) 2005-06-02
DE69924999T2 (de) 2006-05-04
CN1170534C (zh) 2004-10-13
CN1312713A (zh) 2001-09-12
WO2000009122A1 (en) 2000-02-24
JP3774118B2 (ja) 2006-05-10
PT1105122E (pt) 2005-08-31
PE20000953A1 (es) 2000-09-26
AU5418599A (en) 2000-03-06
ATE293970T1 (de) 2005-05-15
ES2242413T3 (es) 2005-11-01
TR200100471T2 (tr) 2001-07-23
CA2340056C (en) 2007-01-09
JP2002522491A (ja) 2002-07-23
BR9912980B1 (pt) 2013-10-22
CA2340056A1 (en) 2000-02-24
EP1105122A1 (en) 2001-06-13
DK1105122T3 (da) 2005-08-08
AR035001A1 (es) 2004-04-14
EP1105122B1 (en) 2005-04-27
KR20010079635A (ko) 2001-08-22
AU761351B2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
BR9912980A (pt) Composição farmacêutica administrável oralmente, utilização de compostos, tablete de mascar e processos para evitar a sìndrome de vazamento anal de óleo
BR9912979A (pt) Composição farmacêutica administrável oralmente, tablete de mascar, cápsula e processo para evitar a sìndrome de vazamento anal de óleo
Duman et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication
Casellas et al. Hydrogen breath test with glucose in exocrine pancreatic insufficiency
MA25284A1 (fr) Composition antioxydante, y compris l&#39;acide de l&#39;acetylene, l-carnitine qui ameliore l&#39;utilisation metabolique du glucose.
YU49483B (sh) Oralni dozni oblik azitromicina
Strong et al. Sulindac metabolism: the importance of an intact colon
ES2421787T3 (es) Forma de dosificación de una vez al día de pramipexol
KR910009254A (ko) 과식 및/또는 과음후 증상을 치료하기 위한 약제학적 조성물 및 방법
TR200401906T4 (tr) Kendini emülsifiye ilaç sistemi, yağ ajanı seçime bağlıdır.
EP0966966A3 (en) Nefazodone dosage form
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
FR2782454B1 (fr) Composition pharmaceutique orale solide comprenant un agent sensible aux acides et/ou peu soluble en milieu aqueux et un desagregeant, et utilisation de cette composition.
SG143257A1 (en) Pregabalin composition
FR2849992B1 (fr) Composition pour une administration par voie orale contenant des capsaicinoides
ID15895A (id) Formulasi untuk menurunkan kolesterol darah dan penyerapan lemak berbagai fungsi
BR0312807A (pt) Composição de filme oralmente consumìvel para transferência de agentes refrescantes de hálito para a cavidade oral, e, método para transferência de um agente refrescante de hálito para a cavidade oral
DE69201480D1 (de) Ethanolaminbenzoatderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
NO964451L (no) Röntgenkontrastblandinger inneholdende farmasöytisk akseptable leirer
GUSTAVSSON et al. Assessment of Campylobacter-like organisms in the postoperative stomach, iatrogenic gastritis, and chronic gastroduodenal diseases: preliminary observations
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L&#39;ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
US4483854A (en) Systemic treatment of psoriasis using certain salicylates
Reiser et al. The effects of cisapride on the quality and tolerance of colonic lavage: a double-blind randomized study
BRPI0506929A (pt) composições de gel macio dermatológicas
Zinkievich et al. Gastric acid is the key modulator in the pathogenesis of non‐steroidal anti‐inflammatory drug‐induced ulceration in rats

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/365, A61K 9/00, A61K 45/08, A61K 47/38, A61P 3/04, A61P 30/04, A61P 43/00

Ipc: A61K 31/365 (2008.04), A61K 9/00 (2008.04), A61K 4

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO UMA VEZ QUE ESTE CONTRARIA O DISPOSTO NOS ARTIGOS 8O, 10 ( VIII ), 11, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.